Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

NCTNCT00417183Other idlong vs flexible

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Status unknown
Phase: Phase 4
Enrollment: 300 participants
Sponsor: Eugonia · Other
Design: Randomized · Open label (no masking)
Countries: 1 country
Greece
Start: Sept 2005
Primary completion: Not stated
Completion: Jun 2007
First posted: 29 Dec 2006 (estimated)
Last update posted: 29 Dec 2006 (estimated)
Conditions: Infertility

Timeline

1 trial

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2005200620072008

Ph 4
Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
NCT00417183
Sept 2005 to Jun 2007

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the "long" protocol, and the flexible GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile patients receiving IVF treatment.

Interventions

Arvekap 0.1 mg (Triptorelin, Ipsen, France)Drug
Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

Ongoing pregnancy per embryo transfer

Secondary outcomes(3)

Biochemical pregnancy per embryo transfer
Clinical pregnancy per embryo transfer
Embryological data

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex: Female
Age: from 21 Years up to 39 Years
Healthy volunteers: Accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Age 18-39 years * Body mass index 18-29 kg/m2 * Menstrual cycle from 24-35 days * Normal basal FSH (\<10 IU/ml) * Normal basal LH (\<10 IU/ml) * Normal basal estradiol (\<80 pg/ml) Exclusion Criteria: * Poor responder patients * Polycystic ovaries

PepBank is a research reference. Talk to a doctor before you use any peptide.